According to the latest GOLD guidelines, in COPD patients with ≥2 moderate or ≥1 severe exacerbations per year despite optimized inhaled bronchodilator therapy and a blood eosinophil count ≥300 cells/µL, which biologic therapies are recommended and how should they be administered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

GOLD Guidelines on Biologics in COPD

The latest GOLD 2026 guidelines now recommend biologic therapies—specifically dupilumab and mepolizumab—as add-on treatment for patients with COPD who have blood eosinophil counts ≥300 cells/µL and continue to experience ≥2 moderate or ≥1 severe exacerbations per year despite optimized triple inhaled therapy (LAMA/LABA/ICS). 1

Which Biologics Are Recommended

The GOLD 2026 report introduces two specific biologics for eosinophilic COPD:

Dupilumab (300 mg subcutaneously every 2 weeks)

  • Blocks the shared receptor for IL-4 and IL-13, key drivers of type 2 inflammation
  • Demonstrated 30-34% reduction in moderate/severe exacerbations versus placebo 2, 3
  • Provides additional benefits beyond exacerbation reduction:
    • Improved lung function (FEV1 increase of 82-83 mL at week 12, sustained through week 52)
    • Better quality of life (SGRQ improvement of -3.4 points at week 52)
    • Reduced respiratory symptoms (E-RS-COPD improvement of -1.1 points)
  • Particularly effective in patients with elevated FeNO ≥20 ppb 4

Mepolizumab (100 mg subcutaneously every 4 weeks)

  • Targets interleukin-5, central to eosinophilic inflammation
  • Demonstrated 21% reduction in moderate/severe exacerbations versus placebo 5
  • Did NOT show significant improvements in quality of life or symptoms beyond exacerbation reduction
  • Requires approximately 4.8 years to prevent one exacerbation, compared to 2.3-3.1 years for dupilumab 4

Patient Selection Criteria

Biologics should be considered when ALL of the following are met:

  1. Blood eosinophil count ≥300 cells/µL (consistent threshold across all trials)
  2. Exacerbation history: ≥2 moderate OR ≥1 severe exacerbation in the previous year
  3. Already on optimized triple inhaled therapy (LAMA/LABA/ICS)
  4. Continued exacerbations despite triple therapy

Important Nuance on the "E" Classification

The GOLD 2026 classification now includes patients with just one moderate exacerbation in Group E 6. However, biologics should NOT be initiated after a single moderate exacerbation—the evidence base and recommendations specifically require ≥2 moderate or ≥1 severe exacerbations 1. A single moderate exacerbation has limited clinical impact at the population level and carries a future exacerbation risk typically below 50% 6.

Choosing Between Dupilumab and Mepolizumab

Dupilumab appears to be the preferred biologic based on the totality of evidence:

  • Broader efficacy profile: Reduces exacerbations AND improves lung function, quality of life, and symptoms 2, 3
  • More efficient exacerbation prevention: Number needed to treat is lower (2.3-3.1 vs 4.8 years to prevent one exacerbation) 4
  • Enhanced effect with biomarker stratification: Particularly effective when FeNO ≥20 ppb 4

Mepolizumab may be considered when:

  • Dupilumab is contraindicated, not tolerated, or not available
  • Cost considerations favor mepolizumab
  • Patient preference for less frequent dosing (every 4 weeks vs every 2 weeks)

Stepwise Approach Before Biologics

Before considering biologics, ensure the following escalation pathway has been completed:

  1. Optimize dual bronchodilation (LAMA/LABA) as the foundation

  2. Add ICS to triple therapy if blood eosinophils ≥300 cells/µL and exacerbations persist 7

  3. Consider additional therapies for persistent exacerbations on triple therapy:

    • Macrolide maintenance therapy (e.g., azithromycin) for appropriate patients with normal QT interval, no drug interactions, and no atypical mycobacterial infection 7
    • Roflumilast for chronic bronchitic phenotype 7
    • N-acetylcysteine for chronic bronchitic phenotype 7
  4. Only after exhausting these options should biologics be added 1

Critical Caveats and Pitfalls

Do NOT step down ICS in high-risk exacerbators

  • Withdrawing ICS increases exacerbation risk, especially harmful when eosinophils ≥300 cells/µL 7
  • Biologics are ADD-ON therapy, not replacements for triple therapy

Blood eosinophil variability

  • Eosinophil counts fluctuate; confirm elevation on multiple occasions when possible
  • The 300 cells/µL threshold is evidence-based from clinical trials but represents a continuum of risk 1

Limited real-world evidence

  • Biologic trials excluded many real-world COPD patients with significant comorbidities
  • Cost-effectiveness remains uncertain 1
  • Long-term safety data beyond 52-104 weeks are limited

Pneumonia risk with ICS

  • Triple therapy increases pneumonia risk (NNH = 33 patients for 1 year) 7
  • However, NNT = 4 patients for 1 year to prevent one exacerbation, favoring benefit over harm 7
  • Biologics do not eliminate the need for ICS in this population

Not for acute exacerbations

  • Biologics are maintenance therapy for exacerbation prevention
  • They have no role in treating acute exacerbations

Administration and Monitoring

Dupilumab: 300 mg subcutaneous injection every 2 weeks (can be self-administered after training)

Mepolizumab: 100 mg subcutaneous injection every 4 weeks (can be self-administered after training)

Monitoring should include:

  • Exacerbation frequency and severity
  • Lung function (FEV1) at 12 weeks and periodically thereafter
  • Quality of life assessments (SGRQ or CAT)
  • Symptom burden
  • Adverse events (injection site reactions, eosinophilia-related complications)
  • Consider FeNO measurement if available to identify dupilumab super-responders

Reassess efficacy at 12-24 weeks: If no reduction in exacerbations or improvement in other outcomes, consider discontinuation and alternative strategies.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.